Anteris Technologies Global vs CollPlant Biotechnologies
AVR and OPHI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AVR and OPHI compare
CollPlant Biotechnologies grew revenue faster over the last twelve months (360% versus 9.0% for Anteris Technologies Global).
CollPlant Biotechnologies keeps more of each dollar of sales as profit, with a net margin of −485% compared with −4637% at Anteris Technologies Global.
CollPlant Biotechnologies scores higher on the StockData Score (9 against 5 for Anteris Technologies Global), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AVR | OPHI |
|---|---|---|
| Size and price | ||
| Market cap | $518M | – |
| Share price | $5.32 | $3.60 |
| Change, 1 year | 44.2% | −81.8% |
| Change, 5 years | – | −98.0% |
| Beta (5Y) | 1.67 | −0.48 |
| Employees | 174 | 39 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 222× | – |
| P/B | 2.3× | – |
| FCF yield | −18.0% | – |
| Growth | ||
| Revenue growth (TTM) | 9.0% | 360% (better) |
| Revenue growth, 5Y average | – | −17.3% |
| Profitability | ||
| Gross margin | 75.8% (better) | 64.8% |
| Operating margin | −4880% | −484% (better) |
| Net margin | −4637% | −485% (better) |
| FCF margin | −4008% | −398% (better) |
| Return on equity | −93.8% (better) | −149% |
| Return on invested capital | −3856% | −1245% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Interest coverage | −615.2× | – |
| Current ratio | 12.45 (better) | 1.57 |
| Altman Z-score | 5.96 | – |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 70.8% | 0.00% |
| Held by insiders | 32.6% | – |
| Insider net buying, 12 months | $44.1M | – |
| Short interest, % of float | 13.8% | – |
Go deeper
- AVR stock overview
- AVR income statement
- AVR valuation and score
- OPHI stock overview
- OPHI income statement
- OPHI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.